Decade-Long Nationwide Trends and Disparities in Use of Comfort Care Interventions for Patients With Ischemic Stroke

Kristie M. Chu, MD; Erica M. Jones, MD; Jennifer R. Meeks, MS; Alan P. Pan, MS; Kathryn L. Agarwal, MD; George E. Taffet, MD; Farhaan S. Vahidy, PhD, MBBS, MPH

BACKGROUND: Stroke remains one of the leading causes of disability and death in the United States. We characterized 10-year nationwide trends in use of comfort care interventions (CCIs) among patients with ischemic stroke, particularly pertaining to acute thrombolytic therapy with intravenous tissue-type plasminogen activator and endovascular thrombectomy, and describe in-hospital outcomes and costs.

METHODS AND RESULTS: We analyzed the National Inpatient Sample from 2006 to 2015 and identified adult patients with ischemic stroke with or without thrombolytic therapy and CCIs using validated International Classification of Diseases, Ninth Revision (ICD-9) codes. We report adjusted odds ratios (ORs) and 95% CI of CCI usage across five 2-year periods. Of 4,249,201 ischemic stroke encounters, 3.8% had CCI use. CCI use increased over time (adjusted OR, 4.80; 95% CI, 4.15–5.55) regardless of acute treatment type. Advanced age, female sex, White race, non-Medicare insurance, higher income, disease severity, comorbidity burden, and discharge from non-northeastern teaching hospitals were independently associated with receiving CCIs. In the fully adjusted model, thrombolytic therapy and endovascular thrombectomy, respectively, conferred a 6% and 10% greater likelihood of receiving CCIs. Among CCI users, there was a significant decline in in-hospital mortality compared with all other dispositions over time (adjusted OR, 0.46; 95% CI, 0.38–0.56). Despite longer length of stay, CCI hospitalizations incurred 16% lower adjusted costs.

CONCLUSIONS: CCI use among patients with ischemic stroke has increased regardless of acute treatment type. Nonetheless, considerable disparities persist. Closing the disparities gap and optimizing access, outcomes, and costs for CCIs among patients with stroke are important avenues for further research.

Key Words: brain ischemia ■ comfort care ■ healthcare disparities ■ outcome assessment ■ services use ■ stroke ■ thrombolytic therapy
CLINICAL PERSPECTIVE

What Is New?
• Across the United States, use of comfort care interventions among adult patients with ischemic stroke steadily increased between 2006 and 2015, including greater use in those treated with intravenous tissue-type plasminogen activator and endovascular thrombectomy.
• National trends in hospital outcomes demonstrate a significant decline in in-hospital mortality relative to all other discharge dispositions, with an increasing proportion of patients with ischemic stroke with comfort care interventions receiving long-term care and home health/hospice care.
• Use of comfort care interventions among patients with ischemic stroke does not prolong length of hospital stay and is associated with lower adjusted costs.

What Are the Clinical Implications?
• Use of comfort care interventions is an increasingly important component of stroke care despite the increase in acute treatment options.
• Further studies and efforts are warranted to reduce disparities and optimize patient-centered outcomes as well as costs for patients with ischemic stroke who are eligible for comfort care interventions.

Nonstandard Abbreviations and Acronyms

| Abbreviation | Description |
|--------------|-------------|
| CCIs         | comfort care interventions |
| EVT          | endovascular therapy |
| IS           | ischemic stroke |
| NIS          | National Inpatient Sample |
| PC           | palliative care |

of pain and symptom relief. However, hospice care is reserved for patients with terminal illness, whereas PC can be helpful at any stage of illness. According to the National Consensus Project for Quality Palliative Care, the definition of PC is “patient and family-centered care that optimizes quality of life by anticipating, preventing, and treating suffering.” In a 2016 policy statement, the American Heart Association/American Stroke Association recognized the value of comfort/palliative care in meeting priority needs of patients with stroke and improving quality of care and outcomes, supporting a system of care that provides patients with access to such interventions in conjunction with specialist-level stroke care. However, persistent disparities in comfort care use among patients with stroke have been identified with respect to sex, race, region, and hospital characteristics.

The goal of this study was to characterize 10-year nationwide trends in use of comfort care interventions (CCIs), including palliative and hospice care, for patients with ischemic stroke (IS) and describe in-hospital outcomes such as mortality, discharge disposition, length of stay (LOS), and costs for patients with IS receiving CCIs, particularly in relation to acute thrombolytic therapy with intravenous tissue-type plasminogen activator (IV tPA) and endovascular thrombectomy (EVT). We hypothesized an increase in CCI use and a decrease in in-hospital mortality across categories of patients with IS who receive CCI.

METHODS

Data Disclosure Statement
All data used in this project are publicly available from Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality (https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp) upon completion of requisite training and data use agreements. All data used for this project were fully deidentified and publicly available, thus not constituting human subjects research; therefore, institutional review board approval was not merited.

Study Design, Data Source, and Case Identification
We conducted a cross-sectional analysis of the National Inpatient Sample (NIS) including data from the years 2006 to 2015. The NIS is a stratified sample of ≈20% of all discharges from US community hospitals and is the largest publicly available all-payer (including the uninsured) inpatient healthcare database in the United States. After applying appropriate sampling weights, it represents 90% of US hospitalizations. The NIS is made available by assimilation of state-level data by the Agency for Healthcare Research and Quality under its Healthcare Costs and Utilization Project. We identified discharge events for adult patients (aged ≥18) with a principal diagnosis of IS using validated International Classification of Diseases, Ninth Revision (ICD-9) codes. Among the adult IS discharge encounters, we tagged records with ICD-9 procedure codes for use of either IV tPA or EVT and for use of CCI services, as has been previously reported. To avoid coding inconsistencies between ICD-9 and International Classification of Diseases, Tenth Revision (ICD-10), we did not include data from the fourth quarter of 2015. For identification of CCI encounters, we used ICD-9 code V66.7, which is flagged when various CCIs such as comfort care, hospice care or PC are used during hospitalization. Prior reports have used this code to identify the influence of PC use on estimates.
of in-hospital mortality, and to describe the use of PC among patients with intracerebral hemorrhage.12,13

Outcomes
We explored the association between CCI use and in-hospital outcomes of death, LOS, and discharge disposition. These outcomes are consistently provided in the NIS across all years of analysis. In addition to in-hospital deaths, we classified discharge disposition into the following categories: home discharge, transfer to acute care hospital, transfer to long-term care facility, and home health care. As per the coding in NIS, long-term care facilities include skilled nursing care facilities, hospice, long-term acute care, and inpatient rehabilitation facilities. LOS is calculated by subtracting the admission date from the discharge date, and same-day events are coded as zero. We calculated cost of hospitalization for each encounter by converting total hospital charges to costs using the Healthcare Costs and Utilization Project’s cost-to-charge ratio files.14 Costs were inflation adjusted for 2015 US dollars using the Chained Consumer Price Index for all urban consumers and medical care services from the US Bureau of Labor Statistics.15

Covariates
Rates of CCI use by each year of analysis were analyzed while describing and adjusting for several demographic, healthcare system, comorbidity, and clinical disease severity variables. We included age, sex, race, insurance type, and socioeconomic status as demographic variables. Hospital bed size, hospital location, and teaching status were included as health system factors. The Charlson comorbidity index, hypertension, diabetes mellitus, heart failure, atrial fibrillation, renal failure, cancer, and coagulopathies were included as comorbidities. The all-patient refined diagnosis-related group is a disease severity measure that incorporates severity of illness subclass and risk of mortality with base diagnosis-related group and is calculated in the NIS using specialized software. Values of all-patient refined diagnosis-related group range from 0 to 4 with increasing level of loss of function. We used all-patient refined diagnosis-related group along with procedures such as ventilator support, tracheostomy, gastric tube, and hemicraniotomy as measures of disease severity.

Statistical Analysis
All analyses used survey design variables with appropriate discharge and trend weights in the NIS to yield nationally representative estimates. We provide descriptive rates of CCI use across 2-year time intervals as a proportion of IS discharges with or without IV tPA and EVT during the same 2-year interval. Mean (SD) and proportions were compared for each covariate across stroke encounters with and without CCI use. A multivariable logistic regression model was fitted to assess independent factors associated with CCI use along with providing trend estimates, with the year 2006 as the reference. The final model included all variables that were statistically (P<0.05) and clinically significant. We fit multivariable logistic, ordinal, and modified Poisson models to estimate the likelihood of death, nonhome discharge disposition, and longer LOS among IS encounters with CCI use as compared with those without CCI use. We report adjusted odds ratios (aORs) and adjusted rate ratios along with 95% CI. Hospitalization costs associated with CCI use were estimated on the basis of coefficients derived from negative binomial generalized linear models. All analyses were conducted using STATA version 16 (StataCorp, College Station, TX). We observed a total of 873 231 encounters with CCI use, which provided adequate power for our multivariable analyses.

RESULTS
Based on our inclusion and exclusion criteria, we identified a total of 4 249 201 IS encounters between January 1, 2006, and September 30, 2015, in the NIS. The mean age was 70.9 (95% CI, 70.9–71.1) years, 52% were women, and 70% were White. Among total IS encounters, 3.8% were coded for CCI use.

Trends in CCI Use
CCI use increased over the 10-year study period, with patients with IS in the 2-year time period of 2014 through 2015 being 4.8 times more likely to receive CCI compared with those in 2006 through 2007 (aOR, 4.80; 95% CI, 4.15–5.55). The increase in CCI use occurred in a stepwise fashion, with significantly higher odds across all five 2-year time periods (aOR, 4.80; 95% CI, 4.15–5.55). The increase in CCI use occurred in the NIS among stroke encounters with and without CCI use. We report adjusted odds ratios (aORs) and adjusted rate ratios along with 95% CI. Hospitalization costs associated with CCI use were estimated on the basis of coefficients derived from negative binomial generalized linear models. All analyses were conducted using STATA version 16 (StataCorp, College Station, TX). We observed a total of 873 231 encounters with CCI use, which provided adequate power for our multivariable analyses.

CCI and Patient/Hospital Characteristics
Bivariate and multivariate analyses of pertinent variables are presented in Table 1. Proxies of overall illness
severity, including all-patient refined diagnosis-related group severity subclass and Charlson comorbidity index, were associated with increased CCI use. Patients who received CCIs had a lower rate of invasive procedures such as percutaneous gastrostomy tube (aOR, 0.32; 95% CI, 0.30–0.35) and tracheostomy (aOR, 0.81; 95% CI, 0.70–0.93).

In the multivariate analysis, several patient and hospital characteristics were independently associated with CCI use, including older age and female sex. CCI use was significantly lower in all non-White races/ethnicities (Black [aOR, 0.59; 95% CI, 0.55–0.62], Hispanic [aOR, 0.72; 95% CI, 0.67–0.78], Asian [aOR, 0.72; 95% CI, 0.66–0.79], and Native American [aOR, 0.74; 95% CI, 0.58–0.93]). Non-Medicare types of insurance and higher income were independently associated with increased CCI use. Hospital characteristics associated with increased CCI use included large hospitals (aOR, 1.13; 95% CI, 1.06–1.21, compared with small hospitals), urban teaching (aOR, 1.13; 95% CI, 1.04–1.22, compared with rural), and Western states (aOR, 1.27; 95% CI, 1.18–1.38, compared with Northeast).

CCIs and In-Hospital Outcomes (Mortality, Discharge Disposition, LOS, and Cost)
CCI use was associated with higher in-hospital mortality (aOR, 15.14; 95% CI, 14.36–15.96). However, 10-year trends in disposition outcomes demonstrate a significant decline in in-hospital mortality relative to all other discharge dispositions (aOR, 0.46; 95% CI, 0.38–0.56), with an increasing proportion of CCI patients with IS receiving long-term care and home health care relative to all other dispositions (aOR, 2.42; 95% CI, 2.03–2.88; Figure 3). Unadjusted analyses indicated that CCI patients with IS were more likely to transfer to acute care hospitals (3.2 times), receive long-term care or home health care (11.3 and 11.7 times), and die in-hospital (174 times) than be discharged home (Table 2).

The mean LOS for CCI patients with IS was 5.9 days, compared with 5.1 days for non-CCI patients (OR, 1.01; 95% CI, 1.01–1.01). Adjusting for all variables except for mortality, the odds of longer LOS in CCI versus non-CCI patients was 0.90 (95% CI, 0.88–0.91). Adjusting for all variables including mortality, the odds of longer LOS in CCI versus non-CCI patients was 0.97 (95% CI, 0.95–0.98).

Average cost per hospitalization in CCI patients was $14 988.21 and $12 873.25, respectively (Table 3). Adjusting for LOS, death, age, and disease severity, average cost per hospitalization in CCI patients was $8724 and $10 405, respectively.

DISCUSSION
Using the largest available database of inpatient health care in the United States, we found a rising trend in CCI use between 2006 and 2015 regardless of acute treatment type, with greater CCI use in patients with IS treated with IV tPA and EVT. Our findings are consistent with prior studies that demonstrate an increase in CCI use among patients with stroke over time. We additionally report that CCI use increased despite acute IS treatment with IV tPA or EVT. In addition, we found significant changes in in-hospital mortality and discharge disposition associated with CCI encounters over the study time period, with a decreasing proportion of CCI patients with IS dying in the hospital and an increasing proportion receiving long-term care.
Table 1. Patient and Hospital Characteristics of Patients With Ischemic Stroke With and Without Comfort Care Interventions

| Patient Characteristics | No Comfort Care Intervention | Received Comfort Care Intervention | OR (95% CI) | aOR (95% CI)* |
|-------------------------|-----------------------------|-----------------------------------|-------------|---------------|
| Total IS, n             | 4,089,140                   | 160,061                           |             |               |
| **Age, y**              |                             |                                   |             |               |
| 18–34                   | 1.15                        | 0.22                              |             |               |
| 35–44                   | 3.24                        | 0.65                              | 1.05 (0.80–1.38) | 1.32 (0.98–1.78) |
| 45–54                   | 10.36                       | 2.78                              | 1.40 (1.09–1.79) | 1.88 (1.44–2.45) |
| 55–64                   | 18.13                       | 7.11                              | 2.04 (1.60–2.60) | 2.69 (2.07–3.50) |
| 65–74                   | 22.21                       | 13.48                             | 3.16 (2.48–4.02) | 5.85 (4.49–7.82) |
| 75–84                   | 26.06                       | 28.58                             | 5.70 (4.48–7.26) | 10.96 (8.39–14.31) |
| ≥85                     | 18.85                       | 47.16                             | 13.01 (10.22–16.56) | 23.44 (17.95–30.61) |
| **Sex**                 |                             |                                   |             |               |
| Female                  | 52.00                       | 63.47                             | 1.60 (1.56–1.64) | 1.56 (1.51–1.60) |
| **Race/Ethnicity**      |                             |                                   |             |               |
| White                   | 69.77                       | 80.70                             | Ref         | Ref           |
| Black                   | 16.89                       | 8.70                              | 0.45 (0.42–0.47) | 0.59 (0.55–0.62) |
| Hispanic                | 7.54                        | 5.35                              | 0.61 (0.57–0.66) | 0.72 (0.67–0.78) |
| Asian/Pacific Islander  | 2.66                        | 2.49                              | 0.81 (0.74–0.89) | 0.72 (0.66–0.79) |
| Native American         | 0.52                        | 0.37                              | 0.62 (0.49–0.78) | 0.74 (0.58–0.93) |
| Other‡                  | 2.62                        | 2.39                              | 0.79 (0.72–0.87) | 0.80 (0.73–0.89) |
| **Insurance status**    |                             |                                   |             |               |
| Medicare                | 65.68                       | 75.13                             | Ref         | Ref           |
| Medicaid                | 7.24                        | 3.25                              | 0.39 (0.37–0.42) | 1.41 (1.30–1.53) |
| Private                 | 19.66                       | 14.11                             | 0.63 (0.59–0.66) | 1.70 (1.58–1.84) |
| Self-pay                | 4.79                        | 2.33                              | 0.42 (0.38–0.48) | 2.10 (1.81–2.43) |
| No charge               | 0.47                        | 0.19                              | 0.36 (0.24–0.53) | 1.82 (1.17–2.84) |
| Other                   | 2.17                        | 4.98                              | 2.01 (1.80–2.24) | 6.09 (5.32–6.98) |
| **Income**              |                             |                                   |             |               |
| Quartile 1              | 30.32                       | 24.49                             | Ref         | Ref           |
| Quartile 2              | 26.45                       | 25.52                             | 1.19 (1.15–1.24) | 1.07 (1.02–1.11) |
| Quartile 3              | 23.36                       | 25.66                             | 1.36 (1.30–1.42) | 1.14 (1.08–1.19) |
| Quartile 4              | 19.88                       | 24.33                             | 1.52 (1.44–1.60) | 1.19 (1.13–1.26) |
| **Hospital size**       |                             |                                   |             |               |
| Small                   | 12.59                       | 11.07                             | Ref         | Ref           |
| Medium                  | 25.65                       | 25.65                             | 1.14 (1.06–1.22) | 1.08 (1.00–1.17) |
| Large                   | 61.76                       | 63.28                             | 1.16 (1.09–1.25) | 1.13 (1.06–1.21) |
| **Hospital type**       |                             |                                   |             |               |
| Rural                   | 12.13                       | 8.99                              | Ref         | Ref           |
| Urban non-teaching      | 38.91                       | 34.13                             | 1.18 (1.10–1.27) | 0.97 (0.89–1.05) |
| Urban teaching          | 48.96                       | 56.88                             | 1.57 (1.46–1.68) | 1.13 (1.04–1.22) |
| **Hospital region**     |                             |                                   |             |               |
| Northeast               | 17.87                       | 17.85                             | Ref         | Ref           |
| Midwest                 | 22.56                       | 22.56                             | 1.00 (0.93–1.08) | 1.12 (1.03–1.21) |
| South                   | 41.24                       | 37.06                             | 0.90 (0.84–0.97) | 1.03 (0.96–1.11) |
| West                    | 18.34                       | 22.52                             | 1.23 (1.14–1.33) | 1.27 (1.18–1.38) |
| **Loss-of-function subclass** |                     |                                   |             |               |
| Unspecified             | 0.01                        | 0.01                              | Ref         | Ref           |
| Minor                   | 11.41                       | 2.78                              | 0.16 (0.05–0.53) | 0.33 (0.07–1.51) |

(Continued)
care and home health care. Overall, our findings suggest that CCI is an increasingly important component of stroke care despite the rise in acute treatment options, with substantial persistent disparities as well as implications for both in-hospital and discharge outcomes.

CCIs Across Demographic and Hospital Groups
Despite the rising trend in CCI use across the study period, there were significant disparities based on patient and hospital characteristics. We found that the rate of CCI use increased with age, consistent with a prior study on hospitalized patients with stroke using the NIS, which showed that less than half of decedents aged <60 received CCI, while all those aged >90 did.8 This suggests a higher emphasis on life-prolonging care with lower use of CCI services before death among younger patients. CCI use was also more common in White patients compared with patients of other racial groups. This finding is consistent with previously described racial disparities in end-of-life care. Prior studies have shown that Black patients with serious illness have lower rates of advance care planning,16 PC use,17 and end-of-life discussions,18 with higher rates of life-prolonging measures.19 Racial disparities in CCI use may in part be due to cultural preferences and practices.20 Racism also plays a complex role in the risk factors that lead to poor outcomes as well as in the allocation of healthcare resources.21 Mechanisms of such disparities need to be further evaluated.

Our results also suggest substantial variation in CCI use depending on hospital size, type, and region. The regional variability that we observed, with lowest adjusted rates in the Northeast, followed by the South, Midwest, and highest rates in the West, is

| Patient Characteristics     | No Comfort Care Intervention | Received Comfort Care Intervention | OR (95% CI) | aOR (95% CI)* |
|-----------------------------|-------------------------------|-----------------------------------|-----------|---------------|
| Moderate                    | 49.89                         | 20.18                             | 0.26 (0.08–0.88) | 0.49 (0.11–2.26) |
| Major                       | 31.11                         | 44.74                             | 0.93 (0.27–3.13) | 1.59 (0.35–7.27) |
| Extreme                     | 7.58                          | 32.29                             | 2.75 (0.81–9.29) | 5.82 (1.27–26.58) |

| Charlson comorbidity index  | No Comfort Care Intervention | Received Comfort Care Intervention | OR (95% CI) | aOR (95% CI)* |
|-----------------------------|-------------------------------|-----------------------------------|-----------|---------------|
| 0–3                         | 27.37                         | 17.59                             | Ref       | Ref           |
| 2–3                         | 43.04                         | 36.58                             | 1.32 (1.27–1.37) | 1.06 (1.02–1.10) |
| ≥4                          | 29.59                         | 45.84                             | 2.41 (2.31–2.51) | 1.43 (1.36–1.50) |

| Clinical characteristics    | No Comfort Care Intervention | Received Comfort Care Intervention | OR (95% CI) | aOR (95% CI)* |
|-----------------------------|-------------------------------|-----------------------------------|-----------|---------------|
| Atrial fibrillation         | 22.47                         | 46.14                             | 2.96 (2.88–3.03) | 1.52 (1.48–1.56) |
| Metastatic cancer           | 1.28                          | 5.26                              | 4.29 (4.06–4.53) | 2.48 (2.31–2.66) |
| Congestive heart failure    | 13.68                         | 24.44                             | 2.04 (1.98–2.10) | 0.87 (0.84–0.90) |
| Depression                  | 9.77                          | 8.75                              | 0.88 (0.85–0.92) | 0.86 (0.82–0.89) |
| Other psych conditions      | 3.23                          | 2.37                              | 0.73 (0.68–0.79) | 0.77 (0.71–0.84) |
| Diabetes mellitus, uncomplicated | 29.01                       | 23.65                             | 0.76 (0.74–0.78) | 0.70 (0.68–0.72) |
| Diabetes mellitus, complications | 6.08                          | 3.63                              | 0.58 (0.55–0.62) | 0.45 (0.42–0.49) |
| Renal failure               | 12.97                         | 16.89                             | 1.36 (1.32–1.41) | 0.81 (0.78–0.84) |
| Coagulopathy                | 2.86                          | 5.08                              | 1.82 (1.72–1.92) | 0.80 (0.75–0.85) |

| Acute treatment type        | No Comfort Care Intervention | Received Comfort Care Intervention | OR (95% CI) | aOR (95% CI)* |
|-----------------------------|-------------------------------|-----------------------------------|-----------|---------------|
| None                        | 94.26                         | 89.81                             | Ref       | Ref           |
| IV tPA                      | 4.93                          | 7.43                              | 1.58 (1.51–1.65) | 1.06 (1.01–1.11) |
| EVT                         | 0.80                          | 2.76                              | 3.61 (3.31–3.93) | 1.10 (1.00–1.21) |

| Inpatient procedures        | No Comfort Care Intervention | Received Comfort Care Intervention | OR (95% CI) | aOR (95% CI)* |
|-----------------------------|-------------------------------|-----------------------------------|-----------|---------------|
| Mechanical ventilation      | 0.01                          | 0.02                              | 1.87 (0.64–5.44) | 0.81 (0.29–2.24) |
| PEG placement               | 4.27                          | 4.10                              | 1.03 (0.97–1.09) | 0.32 (0.30–0.35) |
| Tracheostomy                | 0.67                          | 0.93                              | 1.39 (1.23–1.57) | 0.81 (0.70–0.93) |
| Hemicraniectomy             | 0.26                          | 0.80                              | 3.14 (2.74–3.59) | 1.88 (1.59–2.21) |

aOR indicates adjusted odds ratio; EVT, endovascular thrombectomy; IS, ischemic stroke; IV tPA, intravenous tissue-type plasminogen activator; OR, odds ratio; and PEG, percutaneous endoscopic gastrostomy.

* Adjusted for female sex, race, tracheostomy, hemicraniectomy, atrial fibrillation, cancer, congestive heart failure, depression, other psychological conditions, uncomplicated diabetes mellitus, diabetes mellitus with complications, renal failure, and coagulopathy.

† Other includes mixed/multiple races as reported in the Healthcare Cost and Utilization Project database National Inpatient Sample (NIS).

P < 0.05.
consistent with prior studies using the NIS to examine CCI use in stroke as well as systemic lupus erythematosus and geriatric patients with colorectal cancer.\(^8\),\(^22\),\(^23\) While these variations may be a reflection of the availability of hospital comfort care programs, a prior study found PC penetration to be highest in the New England states, followed by Pacific, Mid-Atlantic, and lowest in South Central states.\(^24\) This suggests a possible gap in the use of available comfort care services in Northeast hospitals for certain conditions such as stroke.

**Changing Trends in Mortality and Discharge Disposition with CCI**

Significant changes in in-hospital outcomes, including mortality and discharge disposition, were observed across the study time period. In-hospital mortality of CCI patients with IS declined by >50% over the 10-year study period compared with all other discharge dispositions. Concurrently, the proportion of CCI patients with IS going on to receive long-term care and home health care increased by >2 times. These findings are consistent with a prior study describing changes in site of death among Medicare fee-for-service patients between 2000 and 2015, which found a steady decrease in overall deaths in acute care hospitals from 32.6% in 2000 to 19.8% in 2015.\(^25\) Among those who died while receiving hospice services, this study found that more deaths occurred in free-standing hospice inpatient units and in the home or community setting in 2015 compared with 2000. The shifting trend in place of death indicates that while fewer patients with stroke are dying in the hospital (in-hospital mortality is decreasing because of improved acute treatment and management), there may still be a significant number of patients with stroke who die in the postacute, long-term care, or community setting following discharge. This may be in line with the wishes and preferences of patients and their families, with the preferred setting for death being at home in the presence of loved ones.\(^26\)–\(^29\) The provision of and access to postdischarge care options are essential to comfort care’s impact on in-hospital outcomes as well as patient-centered goals of care.

**CCI, LOS, and Cost**

CCI use was found to have significant implications for LOS and hospitalization costs. The mean LOS for CCI patients with IS was 5.9 days compared with 5.1 days for non-CCI patients. The difference between 5.9 and 5.1 days may seem negligible, but an average increase in LOS of =1 day (reduction in 1 overnight stay) is likely to have important resource implications at the population level. When adjusted for all variables except for mortality, the odds of longer LOS in CCI versus non-CCI patients was 0.90, then moved to 0.97 when adjusted for mortality as well, trending toward at least an equal, if not shorter, LOS in CCI patients compared with non-CCI patients. This finding is consistent with a prior study on

---

**Table 2. Discharge Disposition Among Patients With Acute Ischemic Stroke With and Without Comfort Care Interventions**

| Discharge Disposition                              | No Comfort Care Intervention, % | Received Comfort Care Intervention, % | OR (95% CI)* |
|----------------------------------------------------|---------------------------------|---------------------------------------|-------------|
| Home                                               | 36.83                           | 2.87                                  | Ref         |
| Transfer to short-term hospital                     | 3.21                            | 0.80                                  | 3.20 (2.70–3.80) |
| Transfer to skilled nursing or other facility      | 42.97                           | 37.80                                 | 11.29 (10.22–12.48) |
| Home health care                                   | 12.83                           | 11.73                                 | 11.74 (10.55–13.05) |
| Died                                               | 3.36                            | 45.47                                 | 173.89 (156.94–192.69) |
| Other                                              | 0.81                            | 1.33                                  | 21.17 (17.10–26.20) |

OR indicates odds ratio.

*Unadjusted estimates.
hospitalized patients with stroke using the NIS, which found that PC encounters were associated with a shorter LOS, suggesting an earlier death through PC and fewer days of aggressive life-sustaining treatment. \textsuperscript{8} Previously published systematic reviews have also demonstrated a pattern of reduced intensive care unit as well as hospital LOS with early PC consultations, decreasing costs as well without impacting mortality. \textsuperscript{30,31}

Average unadjusted cost per hospitalization in CCI patients was \(\approx 16\%\) higher compared with non-CCI patients. Adjusting for LOS, death, age, and disease severity, average cost per hospitalization in CCI patients was \(\approx 16\%\) lower compared with non-CCI patients. Prior studies have found that estimating the association of PC consultation with hospital costs requires incorporating time from admission to consultation. \textsuperscript{32,33}

Our use of ICD-9 coding to identify CCI encounters within the NIS limits our ability to know when these encounters took place, whether early or late during each hospitalization. Our findings suggest that patients IS perhaps receive CCI services late during their hospitalization, given that cost per hospitalization changes from relatively higher to relatively lower with CCI versus non-CCI when adjusted for LOS and variables of disease severity. While early PC consultation has been shown to result in decreased costs as well as earlier referral to more appropriate levels of care, one prospective cohort study of patients with advanced cancer found that early as well as late PC consultation resulted in cost savings from both reduced LOS and intensity of treatment. \textsuperscript{34–36}

### Limitations

Limitations of this study include its observational design using retrospective analysis of the NIS database. Adjusted estimates therefore represent associations. Nonetheless, the NIS is the largest all-payer inpatient database in the United States, representing 90% of US hospitalizations, and is ideally suited to provide national trend estimates. The NIS does not include information regarding patients’ baseline level of function or whether they have advance directives, both of which are important factors that influence CCI use.

It is noteworthy that within our study time period, the NIS underwent redesign, raising the possibility that trend estimates across 2011 and 2012 may not be stable. To address this possibility, we used trend weights. In addition to the above limitations, we used ICD-9 coding to identify IS as well as CCI encounters. ICD-9 coding is usually performed by the billing departments of hospitals on the basis of provider documentation, which may vary across hospitals and geographic regions. Prior studies have shown that ICD-9 codes for IS have consistently high (at least \(>80\%\)) positive predictive value. \textsuperscript{9,37} The use of the V66.7 code for PC has been shown in one study to have low sensitivity and high specificity in the identification of PC consultation, while another study showed a 98\% positive predictive value. \textsuperscript{38,39} It is possible that patients with the V66.7 procedure code did not receive PC services, especially since specialty PC is not available at all hospitals. Moreover, ICD-9 coding and documentation of PC encounters does not fully reflect the degree of PC services that patients receive. PC services encompass more than what is identified through billing and include holistic and patient- and family-centered care that focuses on quality of life and symptom management. Therefore, our results more precisely indicate trends and associates of a broader category of comfort care. It is also possible that our observations indicate an increase in the coding of CCI itself rather than an increase in the actual use of CCI, but the trends observed in this study correlate with other studies, suggesting proper use of the ICD-9 code.

### CONCLUSIONS

CCI use among patients with IS has increased over time regardless of acute treatment type. Acute treatment with IV tPA and EVT was associated with higher CCI use. Despite increased trends in CCI use, considerable sex, race, and geographic disparities persist at the national level. Outcome trends over time indicate lower in-hospital mortality with higher rates of discharge to long-term care and home health/hospice with CCI use. Comfort care is becoming an increasingly important

---

### Table 3: Cost/Hospitalization (in 2015 US Dollars) Among Patients With Ischemic Stroke With and Without Comfort Care Interventions

| Intervention                      | Cost/Hospitalization, 2015 US Dollars (95% CI) | OR (95% CI) | Adjusted Cost/Hospitalization, 2015 US Dollars (95% CI) | aOR (95% CI)* |
|-----------------------------------|-----------------------------------------------|-------------|--------------------------------------------------------|---------------|
| Without comfort care intervention | 12 873.25 (12 742.53–13 003.96)               | Ref         | 10 405.62 (10 327.67–10 483.57)                        | Ref           |
| With comfort care intervention    | 14 988.21 (14 645.71–15 330.71)               | 1.16 (1.14–1.19) | 8724.07 (8599.30–8848.85)                              | 0.84 (0.83–0.85) |

aOR indicates adjusted odds ratio; and OR, odds ratio.

*Adjusted for length of stay, death, age, and disease severity.
component of stroke care, and further studies are warranted to reduce disparities and optimize access, outcomes, and costs for those who need it.

**ARTICLE INFORMATION**

Received October 13, 2020; accepted February 1, 2021.

**Affiliations**

From the Department of Neurology, McGovern Medical School at the University of Texas Health Science Center at Houston, TX (K.M.C., E.M.J.); Center for Outcomes Research, Houston Methodist Hospital, Houston, TX (U.R.M., A.P.P., F.S.V.); Department of Geriatric Medicine, Baylor College of Medicine, Houston, TX (K.L.A., G.E.T.); and The Houston Methodist Neurological Institute, Houston Methodist, Houston, TX (F.S.V.)

**Acknowledgments**

The authors thank Jacob M. Kolman, MA, scientific writer for the Center for Outcomes Research, Houston Methodist Research Institute, for his review of the language and format of this manuscript.

**Sources of Funding**

Dr Chu and Dr Jones were supported by National Institutes of Health grant ST32NS070412-22.

**Disclosures**

None.

**REFERENCES**

1. Heron M. Deaths: leading causes for 2017. Natl Vital Stat Rep. 2019;68:1–77.
2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141:E139–E596. DOI: 10.1161/CIR.0000000000000757.
3. Creutzfeldt CJ, Longstreth WT, Holloway RG. Predicting decline and survival in severe acute brain injury: the fourth trajectory. BMJ. 2015;351:4–7. DOI: 10.1136/bmj.j3904.
4. Holloway RG, Arnold RM, Creutzfeldt CJ, Lewis EF, Lutz BJ, McCann RM, Rabinstein AA, Saposnik G, Sheth KN, Zahraneh DB, et al. Palliative and end-of-life care in a stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1887–1916. DOI: 10.1161/STR.0000000000000015.
5. What are palliative care and hospice care? National Institute on Aging. Available at: http://www.nia.nih.gov/health/what-are-palliative-care-and-hospice-care. Accessed January 19, 2021.
6. National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care. 3rd ed. Richmond, VA: National Coalition for Hospice and Palliative Care; 2013:12.
7. Braun LT, Grady KL, Kutner JS, Adler E, Berlinger N, Boss R, Buter J, Enguidanos S, Fribert S, Gardner TJ, American Heart Association Advocacy Coordinating Committee, et al. Palliative care and cardiovascular disease and stroke: a policy statement from the American Heart Association/American Stroke Association. Circulation. 2016;134:e198–e225. DOI: 10.1161/CIR.0000000000000438.
8. Singh T, Peters SR, Tirschwell DL, Creutzfeldt CJ. Palliative care for hospitalized patients with stroke: results from the 2010 to 2012 National Inpatient Sample. Stroke. 2017;48:2534–2540. DOI: 10.1161/STROKEAHA.117.016893.
9. McCormick N, Bhole V, Lacalle D, Avina-Zubieta JA. Validity of diagnostic codes for acute stroke in administrative databases: a systematic review. PLoS One. 2015;10:e0135834. DOI: 10.1371/journal.pone.0135834.
10. Saber H, Navi BB, Grottja JC, Kamel H, Bamishiroiya A, Vahidy FS, Chen PR, Blackburn S, Savitz SI, Mcullough L, et al. Real-world treatment trends in endovascular stroke therapy. Stroke. 2019;50:683–689. DOI: 10.1161/STROKEAHA.118.023967.
11. Moradiya Y, Crystal H, Valsamis H, Levine SR. Thrombolytic utilization for ischemic stroke in US hospitals with neurology residency program. Neurology. 2013;81:1986–1995. DOI: 10.1212/WNL.0000000000000391.
12. Cassel JB, Jones AB, Meier DE, Smith TJ, Spragena LH, Weissman D. Hospital mortality rates: how is palliative care taken into account? J Pain Symptom Manage. 2010;40:914–925. DOI: 10.1016/j.jpainsymman.2010.07.005.
13. Murthy SB, Moradiya Y, Hanley DF, Ziai WC. Palliative care utilization in nontraumatic intracerebral hemorrhage in the United States. Crit Care Med. 2016;44:575–582. DOI: 10.1097/CCM.0000000000001391.
14. HCUP-US cost-to-charge ratio files. Available at: https://www.hcup-us.ahrq.gov/db/state/costtocharge.jsp. Accessed October 2, 2019.
15. Consumer Price Index (CPI) Databases: U.S. Bureau of Labor Statistics. Available at: https://www.bls.gov/cpi/data.htm. Accessed October 2, 2019.
16. Narang AK, Wright AA, Nicholas LH. Trends in advance care planning in patients with cancer: results from a national longitudinal survey. JAMA Oncol. 2015;1:601–608. DOI: 10.1001/jamaoncol.2015.1976.
17. Rush B, Hertz P, Bond A, McDermid RC, Ceila L. Use of palliative care in patients with end-stage COPD and receiving home oxygen: national trends and barriers to care in the United States. Chest. 2017;151:41–46. DOI: 10.1016/j.chest.2016.06.023.
18. Mack J, Paulk E, Viswanath K, Prigerson H. Black-white disparities in effects of communication on medical care received near death. Arch Intern Med. 2013;170:1534–1540. DOI: 10.1001/archinternmed.2010.322.
19. George BP, Kelly AG, Schneider EB, Holloway RG. Current practices in feeding tube placement for US acute ischemic stroke inpatients. Neurology. 2014;83:874–882. DOI: 10.1212/WNL.0000000000000764.
20. Cervantes L, Jones J, Linas S, Fischer S. Qualitative interviews exploring palliative care perspectives of Latinos on dialysis. Clin J Am Soc Nephrol. 2017;12:788–798. DOI: 10.2215/CJN.02690619.
21. Williams O, Oviabiele B. Stroking out while Black—the complex role of racism. JAMA Neuro. 2020;7:1343–1344. DOI: 10.1001/jamaneurorad.2020.3510.
22. Yu KG, Shen JJ, Kim PC, Kim SJ, Lee SW, Byun D, Yoo JW, Hwang J. Trends of hospital palliative care utilization and its associated factors among patients with systemic lupus erythematosus in the United States From 2005 to 2014. Am J Hosp Palliat Care. 2019;37:164–171. DOI: 10.1177/1049909119891999.
23. Heller DR, Jean RA, Chiu AS, Feder St, Kurbatov V, Cha C, Khan SA. Regional differences in palliative care utilization among geriatric colorectal cancer patients needing emergent surgery. J Gastrointest Surg. 2019;23:153–162. DOI: 10.1007/jg3-018-3929-0.
24. Dunovanovsky T, Augustin R, Rogers M, Lettang K, Meier DE, Morrison RS. The growth of palliative care in U.S. hospitals: a status report. J Palliat Med. 2016;19:8–15. DOI: 10.1089/jpm.2015.0351.
25. Teno JM, Gozalo P, Trivedi AN, Bunker J, Lima J, Ogarek J, Mor V. Site of death, place of care, and health care transitions among US Medicare beneficiaries, 2000–2015. JAMA. 2018;320:264–271. DOI: 10.1001/jama.2018.8981.
26. Fischer S, Min SJ, Cervantes L, Kutner J. Where do you want to spend your last days of life? Low concordance between preferred and actual site of death among hospitalized adults. J Hosp Med. 2013;8:178–183. DOI: 10.1002/jhm.2018.
27. Meier EA, Gallegos JV, Montross-Thomas LP, Depp CA, Irwin SA, Jeste DV. Defining a good death (successful dying): literature review and a call for research and public dialogue. Am J Geriatr Psychiatry. 2016;24:261–271. DOI: 10.1016/j.ajp.2016.01.035.
28. Singer PA, Martin DK, Kelner M. Quality end-of-life care. JAMA. 1999;281:163–168. DOI: 10.1001/jama.281.2.163.
29. Woodman C, Baille J, Sivell S. The preferences and perspectives of family caregivers towards place of care for their relatives at the end-of-life. A systematic review and thematic synthesis of the qualitative evidence. BMJ Support Palliat Care. 2016;6:418–429. DOI: 10.1136/bmjspcare-2014-000794.
30. Kyerenteng K, Gagnon LP, Thavorn K, Heyland D, D’Egidio G. The impact of palliative care consultation in the ICU on length of stay: a systematic review and cost evaluation. J Intensive Care Med. 2018;33:346–353. DOI: 10.1177/0885066616643292.
31. Khandelwal N, Kross EK, Engelberg RA, Coe NB, Long AC, Curtis JR. Estimating the effect of palliative care interventions and advance care planning on ICU utilization: a systematic review. Crit Care Med. 2015;43:1102–1111. DOI: 10.1097/CCM.0000000000000852.

32. May P, Normand C. Analyzing the impact of palliative care interventions on cost of hospitalization: practical guidance for choice of dependent variable. J Pain Symptom Manage. 2016;52:100–106. DOI: 10.1016/j.jpainsymman.2016.01.009.

33. May P, Garrido MM, Cassel JB, Kelley AS, Meier DE, Normand C, Smith TJ, Stefanis L, Morrison RS. Prospective cohort study of hospital palliative care teams for inpatients with advanced cancer: earlier consultation is associated with larger cost-saving effect. J Clin Oncol. 2015;33:2745–2752. DOI: 10.1200/JCO.2014.60.2334.

34. Fitzpatrick J, Mavissakalian M, Luciani T, Xu Y, Mazurek A. Economic impact of early inpatient palliative care intervention in a community hospital setting. J Palliat Med. 2018;21:933–939. DOI: 10.1089/jpm.2017.0416.

35. May P, Normand C, Cassel JB, Del Fabbro E, Fine RL, Menz R, Morrison CA, Penrod JD, Robinson C, Morrison RS. Economics of palliative care for hospitalized adults with serious illness: a meta-analysis. JAMA Intern Med. 2018;178:820–829. DOI: 10.1001/jamainternmed.2018.0750.

36. May P, Garrido MM, Cassel JB, Kelley AS, Meier DE, Normand C, Smith TJ, Morrison RS. Cost analysis of a prospective multi-site cohort study of palliative care consultation teams for adults with advanced cancer: where do cost-savings come from? Palliat Med. 2017;31:378–386. DOI: 10.1177/0269216317690098.

37. Olson KL, Wood MD, Delate T, Lash Lj, Rasmussen J, Denham AM, Merenich JA. Positive predictive values of ICD-9 codes to identify patients with stroke or TIA. Am J Manag Care. 2014;20:e27–e34.

38. Hua M, Li G, Clancy C, Morrison RS, Wunsch H. Validation of the V66.7 code for palliative care consultation in a single academic medical center. J Palliat Med. 2017;20:372–377. DOI: 10.1089/jpm.2016.0363.

39. Feder SL, Redeker NS, Jeon S, Schulman-Green D, Womack JA, Tate JP, Bedimo RJ, Budoff MJ, Butt AA, Crothers K, et al. Validation of the ICD-9 diagnostic code for palliative care in patients hospitalized with heart failure within the Veterans Health Administration. Am J Hosp Palliat Care. 2018;35:959–965. DOI: 10.1177/1049909117747519.